{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042340","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.386811+00:00","generated_at":"2026-05-24T10:20:44.549658+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Two additional AML patients achieve remission in Cohort 2 of RAINIER trial; 90% response rate","bullets":["Two additional AML patients in Cohort 2 of RAINIER trial achieved remission within 30 days of treatment.","Overall 9 of 10 frontline AML patients achieved remission with mipletamig + ven/aza triplet, vs 66% doublet benchmark.","Complete remission rate (CR) of 70% with triplet outperforms 36% CR from Viale-A ven/aza only study.","No cytokine release syndrome (CRS) observed in RAINIER trial to date; all remissions ongoing.","Cohort 2 enrollment nearing completion; six patients planned at 18 mcg dose level."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042340","json":"https://secwatch.observer/filing/0000950170-25-042340.json","markdown":"https://secwatch.observer/filing/0000950170-25-042340.md","text":"https://secwatch.observer/filing/0000950170-25-042340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025042340/0000950170-25-042340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025042340/apvo-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:20:44.549658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}